The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
The co-leader of President-elect Donald Trump’s initiative to cut government spending has a financial stake in the biotech ...
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of ...
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a ...
The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...
On Friday, the FDA approved BridgeBio Pharma, Inc.’s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) ...
The U.S. Food AND Drug Administration (FDA) has granted accelerated approval of a new drug for treating bilary tract cancer ...
The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...